Biologic drug survival in Israeli psoriasis patients

Guy Shalom, Arnon D. Cohen, Michael Ziv, Cohen Barak Eran, Ilan Feldhamer, Tamar Freud, Eitan Berman, Shirley Oren, Emmilia Hodak, Lev Pavlovsky*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

55 Scopus citations

Abstract

Background Drug survival is defined as the time period of treatment with a certain drug until its cessation. The role of previous exposure to traditional systemic treatments in biologic survival is still unknown. Objective To investigate the drug survival rates of biologic treatments in patients with psoriasis and to identify predictor factors. Methods Survival analysis was performed on patients with severe psoriasis who received adalimumab, infliximab, etanercept, and ustekinumab for treatment of psoriasis, drawn from the Clalit Health Services database. Multivariate analysis was performed adjusting for demographic variables; metabolic syndrome and its components; psoriatic arthritis; biologic naivety; coadministration of methotrexate, acitretin, or cyclosporine; and previous standard systemic treatment exposure. Results Among 907 patients treated with 1575 biologic treatments, ustekinumab had a significantly higher survival rate than tumor necrosis factor inhibitors. Biologic naivety and concomitant methotrexate intake were positive predictors for drug survival, whereas the female sex and the duration of previous systemic treatments were negative predictors. Limitations Data regarding disease severity or duration could not be drawn from the Clalit Health Services database. Conclusion Ustekinumab had better retention rates in comparison with other investigated biologics in patients with severe psoriasis, most of whom used it as a third line therapy.

Original languageEnglish
Pages (from-to)662-669.e1
JournalJournal of the American Academy of Dermatology
Volume76
Issue number4
DOIs
StatePublished - 1 Apr 2017

Keywords

  • adalimumab
  • biologic medications
  • drug survival
  • etanercept
  • infliximab
  • psoriasis
  • ustekinumab

Fingerprint

Dive into the research topics of 'Biologic drug survival in Israeli psoriasis patients'. Together they form a unique fingerprint.

Cite this